BioSpace News Archive

Prothena Corporation plc, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, reported financial results for the fourth quarter and full year 2023.

CooperCompanies announced that its four-for-one stock split will become effective on Friday, February 16, 2024, at 5:00 PM ET, and trading is expected to begin on a stock split-adjusted basis at market open on Tuesday, February 20, 2024, under the existing trading symbol “COO”.

Senseonics Holdings, Inc. announced that it plans to release its fourth quarter and full year 2023 financial results after market close on Thursday, February 29, 2024.

Agile Therapeutics, Inc. announced it has been granted an extension by Nasdaq to regain compliance with the stockholders’ equity requirement for continued listing and provided performance update for full year 2023.

Nyxoah SA announced that the Company will release financial results for the fourth quarter and financial year 2023 on Tuesday, March 5, 2024, after market close.

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announced financial results for the fourth quarter and full year ended December 31, 2023.

Astellas Pharma Inc. announced that Japan’s Ministry of Health, Labour and Welfare has granted priority review for the company’s Supplemental New Drug Application for PADCEV™ with KEYTRUDA® as a combination therapy for the first-line treatment of adult patients with previously untreated locally advanced or metastatic urothelial cancer.

Astellas Pharma Inc. and Kelonia Therapeutics announced that Xyphos Biosciences, Inc., and Kelonia have entered into a research collaboration and license agreement to develop novel Immuno-Oncology therapeutics.

Modular Medical, Inc. announced that it has priced its underwritten public offering of 9,090,910 shares of its common stock, led by Manchester Explorer, L.P., which is managed by Jeb Besser, Modular Medical’s Chief Executive Officer, and Morgan Frank, a member of the Company’s board of directors, and other existing institutional investors.

PTC Therapeutics, Inc. announced that the company will host a webcast conference call to report its fourth quarter and full year 2023 financial results and provide an update on the company’s business and outlook on Thursday, Feb. 29, at 4:30 p.m. EST.